Diabetic injection for weight loss on the NHS: your real options in 2025–26

What the NHS actually offers right now, and who qualifies

The phrase "diabetic injection for weight loss" reflects a genuine piece of history: medicines like semaglutide were first prescribed for type 2 diabetes before trials showed substantial weight reduction in people without diabetes too. Today the licensed weight-management versions (Wegovy and Mounjaro) are distinct products prescribed under their own criteria, separate from the diabetes indication.

On the NHS, tirzepatide became available through GP practices from April 2026 under a new contract arrangement, though GP participation is optional and patchy. The current qualifying threshold is a BMI of 40 or above combined with four or more of five specified conditions: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. A second cohort (BMI 35–39.9 with four or more of those conditions) opened in June 2026. Even patients who meet the criteria must join a wraparound diet and activity programme, and availability still varies by area. The phased NHS rollout is described in detail separately, but the short version is: most people asking this question do not yet qualify for the NHS route, or face a meaningful wait.

Wegovy on the NHS is available through specialist weight management services under NICE's appraisal TA875, but those services have long waiting lists, and the appraisal limits use to a maximum of two years within a multidisciplinary setting. Scotland, Wales and Northern Ireland operate different thresholds; if you are outside England, eligibility criteria for weight loss injections on the NHS are worth checking locally.

The private route: same clinical rigour, no referral needed

A private prescription bypasses the waiting list but not the clinical assessment. Any legitimate online pharmacy offering these medicines must have you assessed by a qualified prescriber before a prescription is issued, that is the legal requirement, full stop. What differs privately is speed and access: there is no GP referral, no NHS eligibility threshold, and no mandatory wraparound programme (though lifestyle changes matter clinically and most good services discuss them).

The private licensed criteria broadly follow the medicine's SmPC: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as prediabetes, hypertension, or high cholesterol. BMI alone does not secure approval; the prescriber reviews your full picture, including any contraindications. For people researching weight-loss injections alongside a diabetes diagnosis, the prescriber will also consider which medicine and which indication applies to your situation.

At nume, every consultation is read and decided by a GPhC-registered Independent Prescriber, a named clinician, the same day. If approved, treatment is dispatched before the end of the working day for free next-working-day delivery via DPD; the box that arrives is plain and unbranded, and a tracking notification comes to your phone so you know exactly when it will land. The consultation, prescription, delivery and ongoing aftercare are covered in one price, with no subscription and no auto-renewals. You can verify our pharmacy registration on the GPhC register.

Safety facts that belong in any honest answer

GLP-1 weight-management injections are not suitable for everyone, and there are situations where the answer is clearly no rather than maybe. Pregnancy and breastfeeding are both firm contraindications, these medicines are not recommended during either, and anyone trying to conceive should stop treatment and allow a wash-out period before attempting pregnancy. Under-18s are not a licensed population for either medicine.

For women of childbearing age, the contraception guidance differs by medicine. Tirzepatide slows gastric emptying in a way that can reduce absorption of oral contraceptive pills; NHS guidance is to add a non-oral method (such as condoms) for the first four weeks of treatment and for four weeks after each dose increase. There is no equivalent evidence of this interaction with semaglutide, though contraception during treatment is advised for both. Anyone on HRT should also discuss their specific formulation with their prescriber, as transdermal options may be preferable on tirzepatide. The NHS England guidance on weight-management injections covers these interactions plainly.

Common side effects are largely gastrointestinal: nausea, constipation, loose stools and reflux are the ones people notice most, typically in the first weeks of a new dose. Severe or persistent stomach pain that radiates to the back warrants urgent medical attention, the MHRA highlighted acute pancreatitis as a known, if infrequent, risk in a January 2026 Drug Safety Update. If in doubt, contact a healthcare professional or call 111 rather than waiting. Side effects or suspected problems with a product can be reported at the MHRA's Yellow Card service.

How to decide which path is right for you

The honest frame for this decision is: NHS access is rationed by clinical need in a specific way; private access is rationed by clinical suitability in a broader way; neither route bypasses medical assessment. If you want to understand how weight loss injections work and what your options look like, that is a conversation for a clinician rather than something a webpage can settle on your behalf.

If you think you might meet the NHS thresholds, it is worth a conversation with your GP. If you do not meet them, or you have already been told you are not yet eligible, or you simply cannot afford to wait, a private consultation with a regulated pharmacy is the practical alternative. For anyone with type 2 diabetes who is also trying to manage their weight, our guidance on weight loss injections on the NHS for diabetes explains how the two indications interact and what prescribers will consider. Our frequently asked questions cover a lot of the practical detail, and our clinical team oversees every prescription decision. Speak to our prescribers to find out whether treatment is right for you, there is no charge for the consultation, and no obligation.